VIR BIOTECHNOLOGY INC (VIR) Stock News
NASDAQ:VIR - Nasdaq - US92764N1028 - Common Stock
VIR Latest News and Analysis
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.
Noteworthy Wednesday Option Activity: MA, AI, VIR
Top movers in Wednesday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's take a look at the stocks that are in motion in today's session.
What's going on in today's session
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
The company is working to engage the immune system to attack cancer cells.
These stocks are moving in today's pre-market session
Get insights into the top gainers and losers of Wednesday's pre-market session.
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
VIR Makes Bullish Cross Above Critical Moving Average
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vir Biotechnology (NASDAQ:VIR) just reported results for the second quarter of ...
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
